Executive summary. European medical cannabis markets differ more in practical access and licensing than in the core pharmaceutical principles applied to product quality. Germany, Portugal, Denmark, the Netherlands and Malta illustrate five different models: large prescription demand, export-oriented production, state-coordinated supply, pilot-programme access and tightly licensed cultivation.
Germany
Germany is Europe's largest and most commercially significant medical cannabis market. Since 1 April 2024, medical cannabis has been governed under the Medical Cannabis Act, or MedCanG, rather than the general narcotics law. BfArM remains the competent authority for medical cannabis traffic. Prescription processes were simplified, but commercial operators still require appropriate permissions, and import or export transactions require permits. The German market combines domestic production with substantial imports and pharmacy dispensing.
Germany’s scale and insurance reimbursement pathway make it the primary market for most European cannabis manufacturers, but its BfArM import requirements are correspondingly the most rigorously enforced in the region.
Portugal
Portugal established its medical cannabis framework through Law 33/2018 and subsequent implementing rules. INFARMED regulates cultivation, manufacture, wholesale, import, export and product authorisation. Portugal has become a major European cultivation and export location because of climate, technical expertise and a clear licensing pathway. Domestic patient access is more limited than the scale of production might suggest. Companies must distinguish authorisation to conduct an activity from authorisation to place a specific preparation or substance on the Portuguese market.
Portugal’s position as an EU GMP manufacturing hub reflects Infarmed’s established inspection programme rather than any relaxation of standard — Portuguese-manufactured product entering Germany still faces full BfArM scrutiny at the point of import.
Denmark
Denmark introduced a medical cannabis pilot programme and has supported domestic cultivation and manufacture under medicines-agency oversight. The framework has been extended while the evidence and access model continue to evolve. Denmark is attractive for pharmaceutical-grade production, but patient volumes and prescribing practices remain distinct from Germany.
Denmark’s pilot programme structure means its regulatory requirements can shift with legislative renewal; suppliers should treat the current framework as time-limited rather than permanent when making long-term market commitments.
The Netherlands
The Netherlands operates a state-coordinated medical cannabis system through the Office of Medicinal Cannabis. The OMC manages contracted production and supply to pharmacies and for export. This creates a more centralised model than open licensing systems. Dutch medical cannabis has historically been supplied as standardised flower through pharmacies.
The Netherlands’ state-monopoly model is unusual in Europe and does not generalise to other markets — a supplier qualified to Dutch standards has not automatically satisfied any other country’s requirements.
Malta
Malta developed a regulated framework for production of cannabis for medicinal and research purposes. The Malta Medicines Authority oversees licensing and GMP-related expectations. The country's model is geared strongly toward licensed production and export rather than a broad domestic prescription market.
Malta’s EU GMP certificates are recognised across the single market under EudraGMDP mutual recognition, but the underlying facility inspection history should still be reviewed independently before committing to a supply relationship.
How to compare markets properly
Companies often compare patient numbers or wholesale prices without examining regulatory friction. The commercially relevant questions are whether the product route is clear, who can prescribe, whether reimbursement exists, how imports are permitted, what evidence the pharmacy or authority requires, and whether the market accepts flower, extracts or finished dosage forms.
Comparing markets on legal status alone is insufficient — reimbursement structure, prescribing restrictions and pharmacy dispensing infrastructure each materially affect real patient access and should be assessed together.
Strategic implications
Germany offers scale but intense competition and price pressure. Portugal offers production and export capability. Denmark offers a structured pharmaceutical environment. The Netherlands offers state-coordinated predictability but less open-market freedom. Malta offers a specialised manufacturing jurisdiction. The right choice depends on whether the company is cultivating, manufacturing, importing, distributing or selling a patient-facing product.
A market entry strategy built on regulatory status alone, without confirming the practical prescribing and reimbursement pathway, risks significant delay between obtaining market access and generating actual patient volume.
Practical reference table
| Country | Regulatory feature | Commercial strength | Primary constraint |
|---|---|---|---|
| Germany | MedCanG and pharmacy market | Large patient and import demand | Price pressure and compliance burden |
| Portugal | INFARMED licensing and export base | Cultivation and manufacturing ecosystem | Limited domestic demand |
| Denmark | Pilot/programme-based access | High pharmaceutical credibility | Smaller market |
| Netherlands | State-coordinated OMC model | Standardised supply and export history | Restricted producer model |
| Malta | Licensed medicinal/research production | Manufacturing and export positioning | Small domestic market |
Decision and implementation path
Common implementation mistakes
Common mistakes include choosing a country because cultivation appears attractive without confirming product access; assuming that GMP certification resolves controlled-drug permissions; using broad cannabis terminology where the active substance is not clearly defined; and relying on commercial claims that exceed the available evidence. A second recurring weakness is treating laboratories, logistics providers or cultivators as external to the pharmaceutical quality system. Outsourced work remains part of the regulated supply chain and requires qualification, agreements, performance review and change notification.
Frequently asked questions
Which country has the largest medical cannabis market?
Germany is generally the largest European prescription market.
Which country is strongest for cultivation and export?
Portugal has developed a substantial licensed production and export sector.
Does a GMP certificate guarantee access to all five markets?
No. Product, import, controlled-drug and national access requirements still apply.
Why is the Netherlands different?
Its medical supply model is coordinated through the Office of Medicinal Cannabis.
Is Malta mainly a patient market?
Its strategic role has been more focused on licensed production and export.
Primary references and guidance
- BfArM: Medical Cannabis and MedCanG information
- INFARMED: Cannabis for Medicinal Purposes
- Danish Medicines Agency: Medical Cannabis Pilot Programme
- Netherlands Office of Medicinal Cannabis
- Malta Medicines Authority: Cannabis for Medicinal and Research Purposes
- EU GMP Guide
- European Pharmacopoeia monograph Cannabis flower (3028)
Confirm the current effective version and national applicability before operational, medical or regulatory use.